Visit Schedule | Enrollment & Allocation | Post allocation | Closeout | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | UNS | EOS | |
Day/Month | Day0 | 1Â M | 3Â M | 6Â M | 9Â M | 12Â M | 15Â M | 18Â M | 21Â M | 24Â M | 27Â M | 30Â M | 33Â M | 36Â M | Â | Â |
 | − 14 |  ± 3 |  ± 7 |  ± 7 |  ± 7 |  ± 7 |  ± 7 |  ± 7 |  ± 7 |  ± 7 |  ± 7 |  ± 7 |  ± 7 |  ± 7 |  |  = 2wks |
Informed Consent | x | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Inclusion/Exclusion criteria | x | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Randomization | x | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
General data and medical history | x | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Medical history of HF | x | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Medical history of CV Diseases | x | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Physical examination | x | x1 | x1 | x1 | x1 | x | x1 | x1 | x1 | x | x1 | x1 | x1 | x | (x) | x |
Heart failure medications | x | x | x | x | x | x | x | x | x | x | x | x | x | x | (x) | x |
Medications of other CVD | x | x | x | x | x | x | x | x | x | x | x | x | x | x | (x) | x |
Other medications | x | x | x | x | x | x | x | x | x | x | x | x | x | x | (x) | x |
TCM Syndrome Diagnosis Questionnaire (SDQHF) | x | x | x | Â | Â | x | Â | Â | Â | x | Â | Â | Â | x | Â | x |
Tongue Image Acquisition | x | x | x | Â | Â | x | Â | Â | Â | x | Â | Â | Â | x | Â | x |
Echocardiogram | x* | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Pregnancy Tests | x | Â | Â | Â | Â | x | Â | Â | Â | x | Â | Â | Â | x | (x) | x |
Blood/urine routine test | x | x | Â | Â | Â | x | Â | Â | Â | x | Â | Â | Â | x | (x) | x |
Biochemical test | x | x | Â | Â | Â | x | Â | Â | Â | x | Â | Â | Â | x | (x) | x |
12-lead ECG | x* | x | Â | Â | Â | x | Â | Â | Â | x | Â | Â | Â | x | (x) | x |
Serum NT-proBNP at local laboratory | x | x | Â | x | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Dispensing IP | x | Â | x | x | x | x | x | x | x | x | x | x | x | x | Â | Â |
Returning IP for accountability | Â | Â | x | x | x | x | x | x | x | x | x | x | x | x | Â | x |
Endpoint Event | Â | x | x | x | x | x | x | x | x | x | x | x | x | x | (x) | x |
Adverse Event | Â | x | x | x | x | x | x | x | x | x | x | x | x | x | (x) | x |
Serious Adverse Event | Â | x | x | x | x | x | x | x | x | x | x | x | x | x | (x) | x |